Shu‐Fu Lin

1.7k total citations
53 papers, 1.3k citations indexed

About

Shu‐Fu Lin is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Molecular Biology. According to data from OpenAlex, Shu‐Fu Lin has authored 53 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Endocrinology, Diabetes and Metabolism, 18 papers in Oncology and 16 papers in Molecular Biology. Recurrent topics in Shu‐Fu Lin's work include Thyroid Cancer Diagnosis and Treatment (20 papers), Cancer-related Molecular Pathways (12 papers) and BRCA gene mutations in cancer (9 papers). Shu‐Fu Lin is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (20 papers), Cancer-related Molecular Pathways (12 papers) and BRCA gene mutations in cancer (9 papers). Shu‐Fu Lin collaborates with scholars based in Taiwan, United States and China. Shu‐Fu Lin's co-authors include Richard J. Wong, Jen‐Der Lin, Ting‐Chao Chou, Chuen Hsueh, Yu‐Yao Huang, Yuman Fong, Yun‐Fan Liaw, Ming‐Whei Yu, Siwei Cheng and Chiou‐Jong Chen and has published in prestigious journals such as PLoS ONE, Advanced Functional Materials and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Shu‐Fu Lin

51 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shu‐Fu Lin Taiwan 23 361 332 320 310 260 53 1.3k
Roland Sedivy Austria 28 778 2.2× 81 0.2× 198 0.6× 607 2.0× 352 1.4× 85 2.5k
Raj K. Tiwari United States 23 804 2.2× 295 0.9× 179 0.6× 318 1.0× 106 0.4× 91 1.6k
Qianchuan He United States 19 586 1.6× 133 0.4× 278 0.9× 153 0.5× 103 0.4× 55 1.4k
Jun Hayashi Japan 26 622 1.7× 86 0.3× 112 0.3× 345 1.1× 396 1.5× 149 2.3k
Xiao‐Jun Tian United States 18 1.1k 2.9× 56 0.2× 129 0.4× 466 1.5× 188 0.7× 62 1.8k
Peter Hufnagl Germany 30 641 1.8× 72 0.2× 119 0.4× 345 1.1× 325 1.3× 135 3.1k
Jianwen Fang United States 17 695 1.9× 105 0.3× 127 0.4× 190 0.6× 114 0.4× 61 1.2k
Sunil K. Joshi United States 26 805 2.2× 74 0.2× 95 0.3× 253 0.8× 230 0.9× 77 2.6k
Julie Klein France 30 1.2k 3.3× 114 0.3× 159 0.5× 182 0.6× 190 0.7× 107 2.5k
Chun Xie United States 29 827 2.3× 45 0.1× 108 0.3× 360 1.2× 142 0.5× 83 2.7k

Countries citing papers authored by Shu‐Fu Lin

Since Specialization
Citations

This map shows the geographic impact of Shu‐Fu Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shu‐Fu Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shu‐Fu Lin more than expected).

Fields of papers citing papers by Shu‐Fu Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shu‐Fu Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shu‐Fu Lin. The network helps show where Shu‐Fu Lin may publish in the future.

Co-authorship network of co-authors of Shu‐Fu Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Shu‐Fu Lin. A scholar is included among the top collaborators of Shu‐Fu Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shu‐Fu Lin. Shu‐Fu Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lin, Shu‐Fu, Chuen Hsueh, Wei‐Yi Chen, Ting‐Chao Chou, & Richard J. Wong. (2025). Targeting Ataxia Telangiectasia-Mutated and Rad3-Related for Anaplastic Thyroid Cancer. Cancers. 17(3). 359–359. 2 indexed citations
2.
Lin, Shu‐Fu, et al.. (2024). Synergistic effects of the combination of trametinib and alpelisib in anaplastic thyroid cancer with BRAF and PI3KCA co-mutations. Heliyon. 10(7). e29055–e29055. 1 indexed citations
3.
Lin, Shu‐Fu, et al.. (2022). Risk Factors and Prognosis for Metastatic Follicular Thyroid Cancer. Frontiers in Endocrinology. 13. 791826–791826. 16 indexed citations
4.
Hsu, Chia‐Jung, et al.. (2022). Outcomes of Patients With Metastatic Differentiated Thyroid Cancer After Excellent Response to Treatment. Frontiers in Endocrinology. 13. 923182–923182. 3 indexed citations
5.
Chou, Ting‐Chao, et al.. (2021). Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer. Cancers. 13(14). 3487–3487. 6 indexed citations
6.
Lin, Shu‐Fu, et al.. (2021). Survival and Death Causes in Thyroid Cancer in Taiwan: A Nationwide Case–Control Cohort Study. Cancers. 13(16). 3955–3955. 4 indexed citations
7.
Lin, Huan-Tang, Mei‐Ling Cheng, Chi-Jen Lo, et al.. (2019). 1H Nuclear Magnetic Resonance (NMR)-Based Cerebrospinal Fluid and Plasma Metabolomic Analysis in Type 2 Diabetic Patients and Risk Prediction for Diabetic Microangiopathy. Journal of Clinical Medicine. 8(6). 874–874. 39 indexed citations
8.
Lin, Jen‐Der, et al.. (2018). The efficacy of radioactive iodine for the treatment of well-differentiated thyroid cancer with distant metastasis. Nuclear Medicine Communications. 39(12). 1091–1096. 14 indexed citations
9.
Lin, Shu‐Fu, Jen‐Der Lin, Chuen Hsueh, Ting‐Chao Chou, & Richard J. Wong. (2018). Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer. Endocrine Related Cancer. 25(10). 853–864. 9 indexed citations
10.
Lin, Shu‐Fu, Jen‐Der Lin, Chuen Hsueh, Ting‐Chao Chou, & Richard J. Wong. (2017). A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer. PLoS ONE. 12(2). e0172315–e0172315. 40 indexed citations
11.
Lin, Shu‐Fu, Jen‐Der Lin, Chuen Hsueh, Ting‐Chao Chou, & Richard J. Wong. (2017). Effects of roniciclib in preclinical models of anaplastic thyroid cancer. Oncotarget. 8(40). 67990–68000. 8 indexed citations
12.
Lin, Fan, et al.. (2016). Study of TCM clinical records based on LSA and LDA SHTDT model. Experimental and Therapeutic Medicine. 12(1). 288–296. 3 indexed citations
13.
Chiang, Kun‐Chun, Sheng‐Fong Kuo, Chih‐Hung Chen, et al.. (2015). MART-10, the vitamin D analog, is a potent drug to inhibit anaplastic thyroid cancer cell metastatic potential. Cancer Letters. 369(1). 76–85. 33 indexed citations
14.
Lin, Shu‐Fu, Yu‐Yao Huang, Jen‐Der Lin, et al.. (2012). Utility of a PI3K/mTOR Inhibitor (NVP-BEZ235) for Thyroid Cancer Therapy. PLoS ONE. 7(10). e46726–e46726. 39 indexed citations
15.
Huang, Chung‐Huei, Tzu‐Chieh Chao, Kun‐Ju Lin, et al.. (2012). Therapeutic outcome and prognosis in young patients with papillary and follicular thyroid cancer. Pediatric Surgery International. 28(5). 489–494. 13 indexed citations
16.
Price, Daniel L., Shu‐Fu Lin, Guy R. Simpson, et al.. (2010). Oncolysis Using Herpes Simplex Virus Type 1 Engineered to Express Cytosine Deaminase and a Fusogenic Glycoprotein for Head and Neck Squamous Cell Carcinoma. Archives of Otolaryngology - Head and Neck Surgery. 136(2). 151–151. 10 indexed citations
17.
Lin, Shu‐Fu, Zhenkun Yu, Christopher C. Riedl, et al.. (2007). Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. Surgery. 142(6). 976–983. 43 indexed citations
18.
Wu, Vin‐Cent, Shuei‐Liong Lin, Shu‐Fu Lin, & Cheng‐Chung Fang. (2004). Treatment of baclofen overdose by haemodialysis: a pharmacokinetic study. Nephrology Dialysis Transplantation. 20(2). 441–443. 60 indexed citations
19.
Yu, Ming‐Whei, Yu‐Chiao Yang, Siwei Cheng, et al.. (2001). Hormonal Markers and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: a Nested Case-Control Study Among Men. JNCI Journal of the National Cancer Institute. 93(21). 1644–1651. 133 indexed citations
20.
Chu, Chung‐Ming, I‐Shyan Sheen, Shu‐Fu Lin, & Yun‐Fan Liaw. (1993). Sex Difference in Chronic Hepatitis B Virus Infection: Studies of Serum HBeAg and Alanine Aminotransferase Levels in 10,431 Asymptomatic Chinese HBsAg Carriers. Clinical Infectious Diseases. 16(5). 709–713. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roland Sedivy Breakdown of academic impact, for papers by Raj K. Tiwari Breakdown of academic impact, for papers by Qianchuan He Breakdown of academic impact, for papers by Jun Hayashi Breakdown of academic impact, for papers by Xiao‐Jun Tian Breakdown of academic impact, for papers by Peter Hufnagl Breakdown of academic impact, for papers by Jianwen Fang Breakdown of academic impact, for papers by Sunil K. Joshi Breakdown of academic impact, for papers by Julie Klein Breakdown of academic impact, for papers by Chun Xie
Rankless by CCL
2026